Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia

Karima Amaador; Catherine Thieblemont; Judith Trotman; Monique C Minnema

doi:10.1002/hon.3210

Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia

Karima Amaador
, Catherine Thieblemont
, Judith Trotman
, Monique C Minnema

Research output: Contribution to journal › Review article › peer-review

28 Downloads (Pure)

Abstract

Marginal Zone Lymphoma (MZL) and Waldenström's Macroglobulinemia (WM) are indolent lymphomas that both arise from post germinal center lymphocytes. Both can secrete a monoclonal protein but high levels are mostly only seen in WM. The MYD88 L256P somatic mutation that is present in an estimated 95% of patients with WM has helped greatly in differentiating the two lymphomas. Several large clinical studies with new drugs have been performed that have provided new treatment options for both MZL and WM patients. In this short review we will discuss the recent literature published and provide some recommendations.

Original language	English
Article number	e3210
Journal	Hematological Oncology
Volume	42
Issue number	6
Early online date	17 Jul 2023
DOIs	https://doi.org/10.1002/hon.3210
Publication status	Published - Nov 2024

Keywords

marginal zone lymphoma
treatment
Waldenstrom macroglobulinemia

Access to Document

10.1002/hon.3210Licence: CC BY

Hematological Oncology - 2023 - Amaador - Recent updates in the indolent lymphomas Update on marginal zone lymphoma andFinal published version, 195 KBLicence: CC BY

Cite this

@article{ad8310e8ba8f45578bf4399315ee3371,

title = "Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenstr{\"o}m's macroglobulinemia",

abstract = "Marginal Zone Lymphoma (MZL) and Waldenstr{\"o}m's Macroglobulinemia (WM) are indolent lymphomas that both arise from post germinal center lymphocytes. Both can secrete a monoclonal protein but high levels are mostly only seen in WM. The MYD88 L256P somatic mutation that is present in an estimated 95\% of patients with WM has helped greatly in differentiating the two lymphomas. Several large clinical studies with new drugs have been performed that have provided new treatment options for both MZL and WM patients. In this short review we will discuss the recent literature published and provide some recommendations.",

keywords = "marginal zone lymphoma, treatment, Waldenstrom macroglobulinemia",

author = "Karima Amaador and Catherine Thieblemont and Judith Trotman and Minnema, \{Monique C\}",

note = "Funding Information: Karima Amaador; none. Catherine Thieblemont: honoraria from Roche, Amgen, Janssen, Celgene, Gilead Science/Kyte Beigene; consulting/advisory role for Roche, Gilead Sciences, Janssen, Celgene, Novartis, Beigene, BMS/Celgene research funding and travel, accommodations, expenses from Roche, Novartis. Judith Trotman; Research funding from Roche, Takeda, Beigene, Cellectar, Janssen, BM. Monique Minnema; Consulting for Janssen Cilag, GSK, CDR life, Pfizer. Speakers Bureau Janssen Cilag, BMS, WebMD, Research funding Beigene Publisher Copyright: {\textcopyright} 2023 The Authors. Hematological Oncology published by John Wiley \& Sons Ltd.",

year = "2024",

month = nov,

doi = "10.1002/hon.3210",

language = "English",

volume = "42",

journal = "Hematological Oncology",

issn = "0278-0232",

publisher = "John Wiley \& Sons Inc.",

number = "6",

}

TY - JOUR

T1 - Recent updates in the indolent lymphomas

T2 - Update on marginal zone lymphoma and Waldenström's macroglobulinemia

AU - Amaador, Karima

AU - Thieblemont, Catherine

AU - Trotman, Judith

AU - Minnema, Monique C

N1 - Funding Information: Karima Amaador; none. Catherine Thieblemont: honoraria from Roche, Amgen, Janssen, Celgene, Gilead Science/Kyte Beigene; consulting/advisory role for Roche, Gilead Sciences, Janssen, Celgene, Novartis, Beigene, BMS/Celgene research funding and travel, accommodations, expenses from Roche, Novartis. Judith Trotman; Research funding from Roche, Takeda, Beigene, Cellectar, Janssen, BM. Monique Minnema; Consulting for Janssen Cilag, GSK, CDR life, Pfizer. Speakers Bureau Janssen Cilag, BMS, WebMD, Research funding Beigene Publisher Copyright: © 2023 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.

PY - 2024/11

Y1 - 2024/11

N2 - Marginal Zone Lymphoma (MZL) and Waldenström's Macroglobulinemia (WM) are indolent lymphomas that both arise from post germinal center lymphocytes. Both can secrete a monoclonal protein but high levels are mostly only seen in WM. The MYD88 L256P somatic mutation that is present in an estimated 95% of patients with WM has helped greatly in differentiating the two lymphomas. Several large clinical studies with new drugs have been performed that have provided new treatment options for both MZL and WM patients. In this short review we will discuss the recent literature published and provide some recommendations.

AB - Marginal Zone Lymphoma (MZL) and Waldenström's Macroglobulinemia (WM) are indolent lymphomas that both arise from post germinal center lymphocytes. Both can secrete a monoclonal protein but high levels are mostly only seen in WM. The MYD88 L256P somatic mutation that is present in an estimated 95% of patients with WM has helped greatly in differentiating the two lymphomas. Several large clinical studies with new drugs have been performed that have provided new treatment options for both MZL and WM patients. In this short review we will discuss the recent literature published and provide some recommendations.

KW - marginal zone lymphoma

KW - treatment

KW - Waldenstrom macroglobulinemia

UR - https://www.scopus.com/pages/publications/85165244444

U2 - 10.1002/hon.3210

DO - 10.1002/hon.3210

M3 - Review article

C2 - 37458281

SN - 0278-0232

VL - 42

JO - Hematological Oncology

JF - Hematological Oncology

IS - 6

M1 - e3210

ER -

Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this